The Oregon Clinical and Translational Research Institute is now accepting letters of intent for the Biomedical Innovation Program: Device, Diagnostic, and Software Development track.
The objective of the Biomedical Innovation Program is to improve human health by moving innovative technologies from academia to the marketplace. The program focuses on bench-to-bedside technology development and commercialization. Formed in partnership with OHSU Technology Transfer & Business Development in 2013, the program has funded a total of seventeen projects, led by a diverse group of principal investigators including clinicians, scientists, and bio-engineers. Several of these projects have achieved proof of concept as a result of Biomedical Innovation Program funding and have been licensed by TTBD to biomedical companies; others have formed the basis for start-up companies.
- Funds up to $80,000 over two years
- Project management and hands-on support from Biomedical Innovation Program staff
- Access to project-specific mentors and experts
OHSU faculty and qualified employees outlined in the PI eligibility guidelines are welcome to apply. Download the RFA here or visit the OCTRI Funding Opportunities webpage for more information. Letters of intent are due on Sept. 26, 2016; detailed submission guidelines can be found in the RFA.
OHSU’s Entrepreneurs-in-Residence and the Biomedical Innovation Program staff will host a workshop on Wednesday, Sept. 14, noon to 1 p.m., Mackenzie Hall 3198 to discuss letters of intent and business development planning. Light lunch will be provided.
Questions? Contact Jonathan Jubera.